Literature DB >> 27313667

Distribution of drug-resistant bacteria and rational use of clinical antimicrobial agents.

Chenliang Zhou1, Xiaobing Chen2, Liwen Wu1, Jing Qu1.   

Abstract

Open wound may lead to infection in patients. Due to overuse of medication, certain bacteria have become resistant to drugs currently available. The aim of the present study was to provide a guide to ameliorate the appropriate and rational use of clinical antimicrobial agents by analyzing the distribution of drug-resistant pathogenic bacteria in patients. Between October 2013 and January 2015, 126 patients were selected at the Department of Orthopedics. Wound secretion samples were collected, and the pathogen bacteria isolated and identified. Identification was performed using an automated identification instrument and the Kirby-Bauer antibiotic method was used to evaluate the bacterial resistance. Of the 126 patients, 118 patients were infected (infection rate, 93.65%). Additionally, 47 strains of gram-positive pathogenic bacteria (39.83%) and 71 strains of pathogenic-gram negative bacteria (60.17%) were identified. The bacteria were most likely to be resistant to penicillin while sensitive to vancomycin and imipenem. Some bacteria were resistant to several antibacterial agents. The results showed that existing risk factors at the Department of Orthopedics were complex and any non-standard procedures were able to cause bacterial infection. There were obvious dissimilarities among infectious bacteria with regard to their sensitivity to various antibacterial agents. Manipulation techniques during the treatment process were performed in a sterile manner and the use of antibacterial agents was required to be strictly in accordance with the results of drug sensitivity tests to provide effective etiologic information and a treatment plan for clinical trials and to reduce the risk of infection by multi-resistant bacteria.

Entities:  

Keywords:  drug sensitivity test; drug-resistance; pathogenic bacteria

Year:  2016        PMID: 27313667      PMCID: PMC4888038          DOI: 10.3892/etm.2016.3239

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


Introduction

Infection is a common complication that occurs in clinical trials (1). Since the majority of patients of the Department of Orthopedics have open wounds, there is a high risk of infection for these patients. Infections may include complicated osteomyelitis, and can be serious and even life threatening (2). In recent years, due to overuse and misuse of antibiotics, certain pathogen bacteria have become resistant to certain drugs. The development of antibiotic-resistant bacteria and their distribution worldwide is the result of many years of constant selection from human overuse and misuse of antibiotics (2). Antibiotic resistance, particularly the problems associated with superbacteria, has become a major public health issue and a global impediment for medical workers and investigators in the 21st century. Since patients in the Department of Orthopedics are easily infected, antibacterial agents are key elements for the treatment of open wounds of patients (3–5). To analyze the distribution of drug-resistant pathogenic bacteria in infected patients and to provide a guide to ameliorate the appropriate use of antibiotics, we analyzed the distribution of drug-resistant bacteria in 126 patients at the Department of Orthopedics. Wound secretion samples were collected, the pathogen bacteria isolated and cultured, and consequently drug-resistance analyses were performed.

Patients and methods

General information

Between October 2013 and January 2015, 126 patients were selected at the Department of Orthopedics, The Fourth Affiliated Hospital of Harbin Medical University (Heilongjiang, China). There were 72 male and 48 female patients with an age range of 16–72 years and an average age of 39.4±10.2 years. Of the 126 patients, 32 cases had infectious arthritis, 48 cases had lower limb open wound infection, 18 cases had soft issue abscess, 21 cases had postoperative infection and 7 cases had other types of infection.

Identification of bacteria and drug sensitivity test

Samples from the wound secretions and pus of patients were taken in a sterile manner and immediately sent for isolation and purification. The isolation and purification protocols were based on The National Clinical Test Regulation of Operation (6). For the identification of pathogen bacteria an automated microorganism identification instrument was used. The Kirby-Bauer antibiotic testing agar diffusion method was used to evaluate bacterial resistance. In this process, Staphylococcus aureus ATCC25923 (Fig. 1), Pseudomonas aeruginosa ATCC27853, Escherichia coli ATCC25922 (Fig. 2) and Klebsiella pneumonia ATCC700603 were used as quality control bacteria.
Figure 1.

Staphylococcus aureus.

Figure 2.

Escherichia coli.

Statistical analysis

Data were analyzed using SPSS 21.0 software (IBM SPSS, Armonk, NY, USA). A t-test was used to make comparisons between different groups. The size of the test was α=0.05. P<0.05 was considered to indicate a statistically significant difference.

Results

Infection rate

Of the samples isolated from 126 patients, 118 samples (infection rate, 93.65%) had bacterial infections.

Pathogen distribution

Isolated pathogens included a variety of gram-positive and -negative bacteria, with gram-negative bacteria constituting the most abundant microorganisms. In total, 47 gram-positive (39.83%) and 71 gram-negative (60.17%) bacterial strains were identified. In the gram-positive group, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus sp. and Staphylococcus pyogenes were identified. In the gram-negative group Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumonia, and Enterobacter cloacae were identified. The most common bacteria were Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Klebsiella pneumonia and Staphylococcus epidermidis (Table I).
Table I.

Isolated pathogens and their distribution.

Pathogen classificationNo. of isolated strains, strainComposition ratio, %
Gram-positive bacteria  4739.83
    Staphylococcus aureus  1613.56
    Staphylococcus epidermidis  1210.16
    Enterococcus faecalis  108.47
    Staphylococcus purulent    65.08
    Staphylococcus haemolyticus    43.39
Gram-negative bacteria  7160.17
    Pseudomonas aeruginosa  2016.95
    Escherichia coli  1512.71
Klebsiella pneumonia  1210.17
    Acinetobacter baumannii  108.47
    Bacillus aerogenes    54.24
    Enterobacter cloacae    43.39
  Others    54.24
Total118100.0

Drug-resistant bacteria

The results of the drug resistance tests showed that several strains were resistant to multiple antibacterial agents. Pathogens such as Acinetobacter baumannii were resistant to the majority of antibacterial agents used in those tests. Gram-positive bacteria were sensitive to vancomycin (7), while almost all of the bacteria were entirely resistant to commonly used antibiotics, such as penicillin and erythromycin. Gram-negative bacteria were sensitive to meropenem and imipenem, while almost completely resistant to sulbactam and ampicillin. We selected typical gram-positive and -negative bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia and Acinetobacter baumannii) to test their resistance to antibacterial agents (Tables II and III).
Table II.

Drug-resistance test results for gram-positive bacteria [n (%)].

Antibacterial agentsStaphylococcus aureus 16Staphylococcus epidermidis 12Enterococcus faecalis 10
Penicillin, n (%)14 (87.5)9 (75)8 (80)
Erythromycin, n (%)15 (93.75)10 (83.33)9 (90)
Gentamicin, n (%)4 (25)8 (66.67)7 (70)
Rifampicin, n (%)6 (37.5)7 (58.33)4 (40)
Levofloxacin, n (%)9 (56.25)7 (58.33)5 (50)
Ciprofloxacin, n (%)6 (37.5)7 (58.33)3 (30)
Ampicillin/sulbactam, n (%)10 (62.5)8 (66.67)4 (40)
Amoxicillin, n (%)3 (18.75)8 (66.67)4 (40)
Cefazolin, n (%)4 (25)9 (75)5 (50)
Ceftriaxone, n (%)3 (18.75)8 (66.67)4 (40)
Vancomycin, n (%)000
Table III.

Drug-resistance test results for gram-negative bacteria [n (%)].

Antibacterial agentsPseudomonas aeruginosaEscherichia coliklebsiella pneumoniaAcinetobacter baumannii
Sulbactam, n (%)18 (90)9 (60)8(66.67)8 (80)
Ampicillin, n (%)19 (95)10 (66.67)9 (75)9 (90)
Gentamicin, n (%)7 (35)8 (53.33)7 (58.33)4 (40)
Ceftazidime, n (%)9 (45)7 (46.67)4 (33.33)4 (40)
Cefepime, n (%)12 (60)7 (46.67)5 (41.67)2 (20)
Ceftriaxone, n (%)9 (45)7 (46.67)3 (25)3 (30)
Cefazolin, n (%)13 (65)8 (53.33)4 (33.33)2 (20)
Ciprofloxacin, n (%)6 (30)8 (53.33)4 (33.33)5 (50)
Norfloxacin, n (%)7 (35)9 (60)5 (41.67)4 (40)
Levofloxacin, n (%)6 (30)8 (53.33)4 (33.33)4 (40)
Meropenem, n (%)1 (5)000
Imipenem0000

Discussion

The overuse of antibiotics has led to the emergence of several drug-resistant bacteria that render the combat against bacterial infections more difficult. The harm caused by these drug-resistant bacteria has become more severe due to the lack of appropriate antibacterial agents in our arsenal (8). In order to achieve a better understanding regarding the drug resistance phenomenon, we need to expand our knowledge of the proper use of antibacterial agents (9). We investigated the occurrence of drug-resistant bacteria in patients at the Department of Orthopedics and analyzed the distribution of pathogens and antibacterial agents. We successfully isolated bacterial pathogens from 118 patients, and identified that those patients were primarily infected with Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae. Of the gram-positive bacteria, Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis had the highest infection rates. These results were consistent with the existing literature (10). Drug sensitivity test results revealed that most gram-negative bacteria were not sensitive to sulbactam and ampicillin, but were sensitive to meropenem and imipenem. Gram-negative bacteria were resistant to penicillin and erythromycin, but sensitive to vancomycin (11). Drug resistance continuously increased (12–14), thus, the work of clinical workers became more cumbersome. Results obtained from previous studies (15–18) revealed that: i) Most patients had open wounds that were easily infected; ii) external wounds caused immune disorders, thereby causing alterations in intestinal flora and leading to internal infections; iii) errors during clinical treatment, non-sterile manipulation and the failure to treat the wounds in a timely manner potentially increased the risk of infection; and iv) failure to sterilize the wound also increased the risk of infection. Since their identification, antibiotics have been crucial agents in the battle against infectious diseases caused by bacteria. Antimicrobial therapy has been an important reason for the significant increase of average life expectancy in the 20th century (19). The increase of drug-resistant bacteria poses a serious threat to public health and the economy. The emergence of superbacteria has indicated that the available pool of antibacterial agents are to be appropriately used and that the appropriate antibacterial agent to which the pathogens are sensitive should be utilized (19). We should only consider the use of newer and more potent antibacterial agents in severe infections caused by multi-resistant bacteria. The most effective manner in which to prevent infection is thorough correct debridement prior to surgery and timely sterilization thereafter (20). The use of antibiotics should be guided by patients' etiological tests (21). In conclusion, we identified that the existing risk factors in the Department of Orthopedics were complex and any non-standard procedures may cause bacterial infection. Additionally, there were evident dissimilarities among infectious bacteria with regard to their sensitivity to various antibacterial agents. Manipulation techniques during the treatment process are to be performed in a sterile manner and the use of antibacterial agents should be strictly in accordance with the results of drug sensitivity tests to provide effective etiologic information and a treatment plan for clinical trials and to reduce the risk of infection by multi-resistant bacteria.
  17 in total

1.  The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs.

Authors:  K B Kirkland; J P Briggs; S L Trivette; W E Wilkinson; D J Sexton
Journal:  Infect Control Hosp Epidemiol       Date:  1999-11       Impact factor: 3.254

Review 2.  Evaluating and managing open skin wounds: colonization versus infection.

Authors:  Annette B Wysocki
Journal:  AACN Clin Issues       Date:  2002-08

3.  Surgical wound infection in general surgery.

Authors:  Odionnys Ramos-Luces; Nelson Molina-Guillén; Werner Pillkahn-Díaz; Julio Moreno-Rodríguez; Agustín Vieira-Rodríguez; José Gómez-León
Journal:  Cir Cir       Date:  2011 Jul-Aug       Impact factor: 0.361

Review 4.  Management of infections caused by vancomycin-resistant gram-positive bacteria.

Authors:  Bindiya Bagga; Jerry L Shenep
Journal:  Pediatr Infect Dis J       Date:  2010-07       Impact factor: 2.129

Review 5.  A methodological systematic review on surgical site infections following spinal surgery: part 1: risk factors.

Authors:  Albert F Pull ter Gunne; Allard J F Hosman; David B Cohen; Michael Schuetz; Drmed Habil; Cees J H M van Laarhoven; Joost J van Middendorp
Journal:  Spine (Phila Pa 1976)       Date:  2012-11-15       Impact factor: 3.468

6.  [From the discovery of antibiotics to emerging highly drug-resistant bacteria].

Authors:  Olivier Meunier
Journal:  Soins       Date:  2015 Jul-Aug

7.  Function-oriented synthesis of simplified caprazamycins: discovery of oxazolidine-containing uridine derivatives as antibacterial agents against drug-resistant bacteria.

Authors:  Kensuke Ii; Satoshi Ichikawa; Bayan Al-Dabbagh; Ahmed Bouhss; Akira Matsuda
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

8.  Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece).

Authors:  H C Maltezou; P Giakkoupi; A Maragos; M Bolikas; V Raftopoulos; H Papahatzaki; G Vrouhos; V Liakou; A C Vatopoulos
Journal:  J Infect       Date:  2009-02-26       Impact factor: 6.072

9.  Genetic basis of antimicrobial resistance and clonal dynamics of carbapenem-resistant Acinetobacter baumannii sequence type 191 in a Korean hospital.

Authors:  Gati Noble Selasi; Asiimwe Nicholas; Hyejin Jeon; Yoo Chul Lee; Jeong Rae Yoo; Sang Taek Heo; Je Chul Lee
Journal:  Infect Genet Evol       Date:  2015-09-02       Impact factor: 3.342

10.  Etiological diagnosis reduces the use of antibiotics in infants with bronchiolitis.

Authors:  Ângela Esposito Ferronato; Alfredo Elias Gilio; Alexandre Archanjo Ferraro; Milena de Paulis; Sandra E Vieira
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

View more
  4 in total

1.  Pseudomonas aeruginosa keratitis: passive immunotherapy with antibodies raised against divalent flagellin.

Authors:  Pariya Mahin Samadi; Parmida Gerami; Ali Elmi; Korosh Khanaki; Sobhan Faezi
Journal:  Iran J Basic Med Sci       Date:  2019-01       Impact factor: 2.699

2.  Current pathogens infecting open fracture tibia and their antibiotic susceptibility at a tertiary care teaching hospital in South East Asia.

Authors:  Md Samiul Islam; Syed Shahidul Islam; Sultana Parvin; Mushfique Manjur; Muhammad Rafiqul Islam; Rabin Chandra Halder; Mohd Sayedul Islam; Syed Khaledur Rahaman; Mobinul Hoque; Md Omar Faruque; A K M Nazmul Haque
Journal:  Infect Prev Pract       Date:  2022-02-03

Review 3.  Application of antimicrobial drugs in perioperative surgical incision.

Authors:  Xu Yang; Xurao Xiao; Lefeng Wang; Yue Ao; Yapeng Song; Huabing Wang; Huanan Wang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-02-03       Impact factor: 3.944

4.  Watching DNA Replication Inhibitors in Action: Exploiting Time-Lapse Microfluidic Microscopy as a Tool for Target-Drug Interaction Studies in Mycobacterium.

Authors:  Damian Trojanowski; Marta Kołodziej; Joanna Hołówka; Rolf Müller; Jolanta Zakrzewska-Czerwińska
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.